Among adults with Stage 2 hypertension by measured blood pressure, more than one in three have never been told they have high blood pressure. That's not a rounding error — it's a structural gap in clinical detection, and it raises a direct question: how big is the problem of undiagnosed high blood pressure?

Key Numbers

• 38.3% of adults with measured Stage 2 hypertension (SBP ≥ 140 or DBP ≥ 90) have never received a hypertension diagnosis
• 401 out of 1,116 adults in this sample with objectively elevated BP had no prior clinical warning
• Stage 2 hypertension — the threshold used here — is not borderline. It's the level at which major cardiovascular guidelines recommend immediate pharmacological intervention

Stage 2 Hypertension Is Not a Gray Zone

To understand the scale of the problem, it helps to be precise about what "undiagnosed" means here. Stage 2 hypertension isn't a close call. A systolic reading at or above 140 mmHg, or diastolic at or above 90 mmHg, sits well past the "elevated" and Stage 1 categories. These are readings that, sustained over time, carry documented associations with stroke, heart failure, and kidney disease. The clinical community has had consensus on this threshold for decades.

Yet in this NHANES sample, 401 adults cleared that bar on measured examination and still reported never being told by a doctor, nurse, or other health professional that they had high blood pressure. That's not a population hovering just above the cutoff. These are people whose readings, if taken in a clinical setting, should have triggered a conversation — and apparently didn't.

The Detection Gap Is Larger Than Most Assume

A 38.3% undiagnosed rate among Stage 2 hypertensives is striking because this population is, by definition, already sick enough to qualify for treatment under current guidelines. The answer to "how big is the problem?" starts there: nearly four in ten people with seriously elevated blood pressure are walking around without knowing it.

The NHANES measurement protocol — multiple readings taken under controlled conditions by trained technicians — is designed to minimize white-coat effects and measurement error. If anything, it's a more rigorous assessment than a single rushed reading in a busy clinic. That means the gap isn't primarily a measurement artifact. These 401 individuals either lack regular access to care, had elevated readings that weren't communicated clearly, or were seen in settings where BP wasn't measured or documented in a way that reached them. The data doesn't distinguish between those pathways — but the outcome is the same: Stage 2 hypertension, unacknowledged.

The Problem Is Bigger Than the Headline Number Suggests

The aggregate 38.3% figure is already alarming, but it likely understates the full scope of the problem in two important ways.

First, it masks whatever variation exists across age, income, insurance status, and race/ethnicity — subgroup breakdowns weren't available in this analysis. Hypertension awareness rates are known to vary substantially across demographic lines in the broader literature, and a single pooled percentage can obscure a much sharper gap in specific populations. The overall rate of 38.3% may be the average of a wide range, with some groups facing a far deeper detection failure.

Second, the scale of the national estimate matters. NHANES uses a complex survey design weighted to represent the U.S. noninstitutionalized civilian population, so these 401 undiagnosed individuals represent a far larger national count when weighted appropriately. The 38.3% is not a local anomaly — it's a nationally representative estimate of a systemic failure to identify people with a treatable, high-risk condition.

Open Questions

Quantifying the problem is a starting point, not an endpoint. The harder questions are about where the breakdown occurs and who bears the cost:

• Among the 38.3% who were never told, how many had seen a primary care provider in the past year — and if so, was their blood pressure measured and simply not communicated, or not measured at all?
• Does the undiagnosed share differ meaningfully by age group? Younger adults are often assumed to be low-risk and may receive less routine BP screening, but they also accumulate years of uncontrolled hypertension before a first diagnosis.
• If these individuals were re-screened and diagnosed, what proportion would qualify for immediate pharmacotherapy under current ACC/AHA guidelines versus lifestyle intervention alone — and does the healthcare system have the capacity to absorb that caseload?

The 38.3% figure answers the question of scale. The questions above are what would be needed to answer the question of cause — and to figure out what closing that gap would actually require.